18m

SEP 0 2 2005

Please type a plus sign (+) inside this box \rightarrow [+]

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.						
DEMAN	E are required to	Application Number		10/717,597		
TRANSMITTAL			Filing Date		November 21, 2003	
FORM			First Named Inventor		Natalie C. TWINE et al.	
(to be used for al	ll correspondence after initio	al filing)	Group Art Unit		1631	
			Examiner Name		Mary K. Zeman	
Total Number of Pages in This Submission 4			Attorney Docket Num	ber	031896-012000 (AM101055)	
		ENCLOSU	RES (check all that apply)			
Fee Transmittal			nent Papers		After Allowance Communication to Group	
☐ Fee Attached	đ		Application)		Appeal Communication to Board of Appeals and Interferences	
Amendment		Drawing Declarate	ion and Power of Attorney		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
☐ Affidavits/de	eclaration(s)	Licensir	g-related Papers		Proprietary Information	
Extension of Tin	na Paguast	Petition			Status Letter	
_	-		to Convert to a Provisional		Application Data Sheet	
Express Abandon	nment Request	Applica		×	Other Enclosure(s):	
Information Disc	closure Statement				PTO Form-1449 citing four (4) U.S. patent, one (1) foreign patent, and	
Document(s)	of Friority	Termina	l Disclaimer	twe	wenty-six (26) non-patent literature	
Response to Mis	sing Parts/	Teducition rectand			documents and three (3) International Search Reports.	
Incomplete Appl	•	CD, Nu	mber of CD(s)		ren Reports.	
Response to Missing Parts under 37 CFR 1.52 or 1.53		Remarks	The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 (031896-012000) for the above identified docket number.			
	SIGNATUI	RE OF APPL	ICANT, ATTORNEY, C	R A	GENT	
Firm or Individual name	Raymond Van Dyke Nixon Peabody LLP 409 9 th Street, N.W. Suite 900 Washington D.C. 2		4,746			
Signature	(del	2/1				
Date	September 2, 2005	0				
	× ×	CERTIFI	CATE OF MAILING			
1	CERTIFICATE (OF MAILIN	G OR TRANSMISSION	۷ [37	CFR 1.8(a)]	
I hereby certify th	I hereby certify that this correspondence is being:					
deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450						
transmi 703-746	· · · · · · · · · · · · · · · · · · ·	e date showr	n below to the United St	ates l	Patent and Trademark Office at	
Date				Sig	gnature	



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re New Patent Application of:)	
Natalie C. TWINE et al)	Group Art Unit: 1631
Serial No.: 10/717,597)	Examiner: Mary K. Zeman
Filed: November 21, 2003)	Confirmation No.: 3640
For: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

The documents cited in the enclosed Form-PTO-1449 are being submitted within three (3) months of the filing of this application or entry into the national stage of this application, or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

In view of the Official Gazette Notice dated August 5, 2003, copies of the cited U.S. patent documents are not included with this Statement. However, copies of the cited foreign patent and non-patent literature documents are enclosed. Also enclosed are copies of International Search Reports, which were issued during the prosecution of the corresponding and related International applications.

Patent Application No.: 10/717,597 Docket No. 031896-012000 (AM101055)

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

The Commissioner is hereby authorized to charge any fees connected with this filing, which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,

Date: September 2, 2005

Raymond Van Dyke Registration No. 34,746

NIXON PEABODY LLP Suite 900 401 9th Street, N.W. Washington, D.C. 20004-2128 Telephone: (202) 585-8000

Facsimile: (202) 585-8080

TATEORMATION

Sheet

1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Complete if Known				
Application Number	10/717,597			
Filing Date	November 21, 2003			
First Named Inventor	Natalie C. TWINE et al.			
Art Unit	1631			
Examiner Name	Mary K. Zeman			
Attorney Docket Number	031896-012000 (AM101055)			

	U.S. PATENT DOCUMENTS					
Examiner Cite No. 1 Number - Kind Code (if known)		U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		U.S 6,288,220	09-11-2001	KAMBARA, H. et al.		
		U.S 6,391,562	05-21-2002	KAMBARA, H. et al.		
		U.S 6,303,301	10-16-2001	MACK, D. H. et al.		
		U.S 6,087,098	06-11-2000	MCKIERNAN, J. M. et al.		

Date Examiner Signature Considered

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Kind Code ³ Country Code ³ Number ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		WO 2002/40717 A2	05-23-2002	MOHANLAL, R.W. et al.			
	1					!	

Examiner Date Considered Signature

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		International Search Report for PCT/US2004/004118, mailed 01/19/2005, 9 sheets	
		International Search Report for PCT/US2004/013587, mailed 01/25/2005, 9 sheets	
		International Search Report for PCT/US2003/037481, mailed 08/23/2005, 3 sheets	
		A. H. KIBBE, Handbook of Pharmaceutical Excipients, 3 rd Edition, Pharmaceutical Press, London, U.K., 2000	
		Affymetrix GeneChip® Expression Analysis, Data Analysis Fundamentals	
		Affymetrix GeneChip® Expression Analysis Technical Manual	
		ARMSTRONG, S. A. et al., MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia, Nat. Genet., 30(1):41-47, 2002	
		BOSMA, A. J. et al., Detection of circulating breast tumor cells by differential expression of marker genes, Clin. Cancer Res., 8(6):1871-1877, 2002	
		COX, D. R., Regression models and life-tables, Meeting of the Research Section of the Royal Statistical Society, pp. 187-220, 1972	
		DAVIS, I. J. et al., Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation, Proc. Natl. Acad. Sci. USA, 100(10):6051-6056, 2003	
		DEPRIMO, S.E. et al., Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification, BMC Cancer, 3(3):1-12, 2003	
		EISEN, M. B. et al., Cluster analysis and display of genome-wide expression patterns, <i>Proc. Natl. Acad. Sci. USA</i> , 95:14863-14868, 1998	

		1.0
Examiner	Date	
LAMINICI		
Cionatum	Considered	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. W673775.1

SEP 0 2 2005 TRADE MASSIBILITY OF THE PROPERTY OF THE PROPE

Sheet

2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known				
Application Number	10/717,597			
Filing Date	November 21, 2003			
First Named Inventor	Natalie C. TWINE et al.			
Art Unit	1631			
Examiner Name	Mary K. Zeman			
Attorney Docket Number	031896-012000 (AM 101080)			

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GOLUB, T. R. et al., Molecular classification of cancer: class discovery and class	
	 	prediction by gene expression monitoring, Science, 286(15):531-537, 1999	
		HILL, A. A. et al., Genomic analysis of gene expression in C. elegans, Science, 290:809-812, 2000	
		HILL, A. A. et al., Evaluation of normalization procedures for oligonucleotide array data	
		based on spiked cRNA controls, Genome Biology, 2 (12):1-13, 2001	
		KOVACS, G. et al., The Heidelberg classification of renal cell tumours, J. Pathol., 183(2):131-133, 1997	
		LOCKHART, D. J. et al., Expression monitoring by hybridization to high-density oligonucleotide arrays, <i>Nat. Biotechnol.</i> , 14(13):1675-1680, 1996	
		MOTZER, R. J. et al., Survival and prognostic stratification of 670 patients with	
		advanced renal cell carcinoma, J. Clin. Oncol., 17(8):2530-2540, 1999	
		PAI, S. M. et al., Population pharmacokinetic analysis of didanosine (2',3'-dideoxyino-	
		sine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or	
		AIDS-related complex, J. Clin. Pharmacol., 32(3):242-247, 1992	
		PARK, W.Y. et al., Identification of radiation-specific responses from gene expression	
		profile, Oncogene, 21(55):8521-8528, 2002	
		PERALBA, JM. et al., Pharmacodynamic evaluation of the rapamycin ester CCI-779,	
		Proceedings of the American Association for Cancer Research Annual Meeting, Volume	
		43, March 2002 (2002-2003), pp. 1000-1001, Abstract No. 4961, and 93 rd Annual Meeting	
	<u> </u>	of the American Association for Cancer Research, San Francisco, CA, April 06-10, 2002	
		POMEROY, S. L. et al., Supplemental Information for Nature's Paper: Prediction of central nervous system embryonal tumour outcome based on gene expression, pp. 1-104, 2002	
		POMEROY, S. L. et al., Prediction of central nervous system embryonal tumour outcome based on gene expression, <i>Nature</i> , 415(6870):436-442, 2002	
		RAMASWAMY, S. et al., Multiclass cancer diagnosis using tumor gene expression signatures, <i>Proc. Natl. Acad. Sci. USA</i> , 98(26):15149-15154, 2001	
	1	SLONIM, D. K. et al., Class prediction and discovery using gene expression data,	
		Proceedings of the Fourth Annual International Conference on "Computational Molecular Biology," TOKYO, JAPAN, pp. 263-272, 2000	
		SNEDECOR, G. W. and COCHRAN, W. G., Correlation, In Statistical Methods, Eight Edition, Chapter 10, pp. 177-195, Iowa State University Press, Ames, Iowa, 1989	
		SU, A. I. et al., Molecular classification of human carcinomas by use of gene expression	
		signatures, Cancer Res., 61:7388-7393, 2001 VAN DE VIJVER, M. J. et al., A gene-expression signature as a predictor of survival in	
	 	breast cancer, N. Engl. J. Med., 347(25):1999-2009, 2002	-
	1	WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication	
		No. 48, pp. 1-45, World Health Organization, Geneva, Switzerland, 1979	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.